BridgeBio’s heart disease drug Attruby sails past prescription estimates
BridgeBio revealed Thursday that prescriptions for its recently approved rare heart disease drug Attruby substantially beat analyst projections — an update that is likely to further boost confidence in...
View ArticleAstraZeneca buys FibroGen’s China unit for local control of anemia drug
AstraZeneca is furthering its presence in China by gaining complete control of FibroGen's subsidiary in the country for about $160 million. The Thursday morning move gives the UK pharma giant a ...
View ArticleDrug packaging manufacturers brace for impact as EU chemical ban looms
The European Union’s proposed ban on “forever chemicals” is expected to become law this year, and investors are beginning to question drug delivery companies and packaging manufacturers on its...
View ArticleTrump’s picks for NIH, CMS say they’ll unload industry investments
The Trump administration's respective nominees for CMS administrator and NIH director, Mehmet Oz and Jay Bhattacharya, disclosed this week that they will divest dozens of investments in biopharma and...
View ArticleIllumina to lay off about 100 people; Incyte’s new AI partnership
Plus, news about 2048 Ventures and Atai Life Sciences: Illumina to lay off 96 employees in San Diego: The company filed a WARN notice in California dated Feb. 13 and said the layoffs are expected ...
View ArticleCharles River’s $1B revenue; Theratechnologies restarts HIV drug supply
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Charles River Laboratories’ stock {$CRL} was up 7% on Wednesday after...
View ArticleWhy UnitedHealth Group is offering 30,000 voluntary buyouts to its employees
An executive for UnitedHealth Group’s insurance arm told employees that not enough people are leaving the company, leading to plans for voluntary buyouts, Endpoints News has learned. The healthcare...
View ArticleIn single case, spinal muscular atrophy drug given before birth spared baby...
A mother took the spinal muscular atrophy drug Evrysdi before giving birth to a baby with the devastating genetic disease. The baby, who went on to receive gene therapy months before they turned 2, has...
View ArticleHow Keymed steered the China-to-US NewCo model in biotech
Keymed Biosciences is a prime example of a young Chinese biotech churning out pipeline candidates ripe for out-licensing to Western drugmakers. The Chengdu-based company, which already markets its own...
View ArticleFirst meeting of CDC vaccine advisors in the Kennedy era is postponed
A meeting of CDC vaccine advisors has been postponed, according to a senior HHS official. "The ACIP meeting will be postponed to accommodate public comment in advance of the meeting," HHS...
View ArticleRoche unveils plans for its DNA sequencer that's been 18 years in the making
Has drug giant Roche finally cracked DNA sequencing? The company has recently claimed it can quickly and accurately decode the genome, in a way that's a major step forward for an industry that’s vital...
View ArticleDrugmakers tell court to keep hospitals out of their 340B rebate suits
Eli Lilly, Bristol Myers Squibb, Sanofi and Novartis are seeking to block a major hospital trade group from intervening in court cases over their proposed 340B drug rebate models. 340B Health and two...
View ArticleTrump’s HHS defends drug price negotiations in Novartis suit
Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare drug price negotiations in court. In a Wednesday court brief, attorneys for...
View ArticleKevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger
Concentra Biosciences, the shell company from Tang Capital that tries to buy out struggling biotechs, has found another target, this time trying to throw a wrench in Acelyrin's merger plans with...
View ArticleMerck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo...
→ Peter Guenter will retire as CEO of Merck KGaA’s healthcare business on June 1, one of several personnel moves that the German pharma announced earlier this week. Global R&D chief ...
View ArticlePfizer ends rollout of Beqvez, putting another dent in hemophilia gene...
Pfizer is ending the development and commercialization of its hemophilia B gene therapy Beqvez, the company confirmed in an emailed statement to Endpoints News. The company cited “limited interest...
View ArticleAchira raises $33M Nvidia-backed seed round, blending AI and physics in biotech
As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ultimately helped lead to his new job. The computational chemist won
View ArticleFDA says Ozempic, Wegovy shortage is over
The FDA said Friday that the shortage of semaglutide, the main ingredient in Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy, has been resolved after more than two years. The move could ...
View ArticleEli Lilly stockpiles $548M of oral weight loss drug ahead of launch
Eli Lilly has amassed a stockpile of soon-to-be-launched drugs and related materials, primarily its oral GLP-1 candidate orforglipron, worth more than half a billion dollars. Orforglipron will be ready...
View Article